Check-Cap Ltd. (CHEK)
| Market Cap | 104.26M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -13.85M |
| Shares Out | 70.45M |
| EPS (ttm) | -0.46 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 10 |
| Last Price | $1.44 |
| Previous Close | $1.48 |
| Change ($) | -0.04 |
| Change (%) | -2.70% |
| Day's Open | 1.51 |
| Day's Range | 1.40 - 1.51 |
| Day's Volume | 1,157,308 |
| 52-Week Range | 0.24 - 4.49 |
Why should you check out CHEK stock? An FDA approval, along with an impressive year-end capital position, provide a solid case for Check-Cap.
ISFIYA, Israel, March 19, 2021 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-...
Check-Cap (CHEK) stock is heading higher on Monday after the company announced approval from the FDA for one of its devices. The post CHEK Stock: The Big FDA News That Has Check-Cap Shares Skyrocketing ...
Check-Cap Ltd (NASDAQ: CHEK) stock is moving higher on heavy volume in the premarket session after the FDA approved its Investigational Device Exemption (IDE) application, permitting Check-Cap to begin ...
ISFIYA, Israel, March 15, 2021 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-...
The technology appears safe, but performance versus standard of care requires a larger, expensive study. It will take a couple years to get readouts from the pivotal US study, providing a lack of catalyst.
Check-Cap Ltd. (CHEK) stock is on the rise Monday despite a lack of news from the maker of the C-Scan colorectal cancer screening device.
CheckCap Ltd. (CHEK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
ISFIYA, Israel, July 23, 2020 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of the ...
CheckCap Ltd. (CHEK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
ISFIYA, Israel, June 5, 2020 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), a clinical-stage medical diagnostics company advancing the development of C-Scan®, the first an...
ISFIYA, Israel, May 27, 2020 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Sca...
CheckCap Ltd. (CHEK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.
Check-Cap Ltd. (CHEK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Check-Cap announced positive final results from its recently completed post-CE approval study evaluating the clinical performance and safety of the C-Scan system.
About CHEK
Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based system that utilizes low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a disposable system attached to the patient's back via biocompatible adhesive skin patches; and C-Scan View software, a client/server-bas... [Read more...]
| Industry Diagnostics & Research | IPO Date Feb 19, 2015 |
| CEO Guy Neev | Employees 65 |
| Stock Exchange NASDAQ | Ticker Symbol CHEK |
Analyst Forecasts
According to one analyst, the rating for Check-Cap stock is "Buy" and the 12-month stock price forecast is 3.00.